<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582878</url>
  </required_header>
  <id_info>
    <org_study_id>SiroMMFStudy 1</org_study_id>
    <nct_id>NCT03582878</nct_id>
  </id_info>
  <brief_title>Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation</brief_title>
  <official_title>Effect of Sirolimus or Mycophenolate With Tacrolimus on Survival of Pancreas and Kidney Grafts in Type 1 Diabetic Recipients After Simultaneous Pancreas and Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective randomized open single center clinical study to compare effect of&#xD;
      sirolimus vs mycophenolate tacrolimus based protocol on pancreas and kidney graft survival in&#xD;
      simultaneous pancreas and kidney recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MTOR (mammalian target of rapamycin) inhibitors represent group of immunosuppressive drugs&#xD;
      with mechanism of T-cell blockade complementary to calcineurin inhibitors. The investigators&#xD;
      presume that combination of sirolimus with tacrolimus will result in better survival of&#xD;
      pancreatic and kidney grafts in simultaneous pancreas and kidney transplantations.&#xD;
&#xD;
      The study is proposed as a single-center extension of EUROSPK 002 trial originally started in&#xD;
      2004 by the EUROSPK Study Group. Recruitment of recipients started in 2004 with approval of&#xD;
      EUROSPK 002. The patient recruitment has continued in a single center (Institute for Clinical&#xD;
      and Experimental Medicine in Prague, Czech Republic) using the same inclusion and exclusion&#xD;
      criteria. The recipients of primary kidney and pancreas transplantation have been randomized&#xD;
      into 2 arms.&#xD;
&#xD;
        -  In the intervention arm sirolimus is added to protocol at a dose of 5 mg immediately&#xD;
           before transplantation, the dose is adjusted to maintained trough sirolimus trough&#xD;
           levels between 5-10ng/ml.&#xD;
&#xD;
        -  In the control arm mycophenolate mofetil was added to tacrolimus. Starting with 1g&#xD;
           before transplantation, the dose has been increased to 1g bid afterwards.&#xD;
&#xD;
      Induction protocol at day 0. consists of ATG (antithymocyte globulin)induction 8mg/kg ,&#xD;
      Tacrolimus 0.05mg/kg, Methylprednisolone 125mg. Dosing of tacrolimus has been adjusted to&#xD;
      maintain trough levels between 5-10ng/ml. ATG was administered at 3mg/kg on days 1.-3.&#xD;
      Steroids have been gradually tapered from a dose of 20 mg prednison orally and withdrawn by&#xD;
      6w after transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2004</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreas graft survival</measure>
    <time_frame>10 years</time_frame>
    <description>Number of failed pancreatic grafts, failure is defined as graft removal, death, retransplantation or return to intensified insulin regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recipient survival</measure>
    <time_frame>10 years</time_frame>
    <description>Long-term recipient survival evaluated with Kaplan-Meyer method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing time</measure>
    <time_frame>1year</time_frame>
    <description>The number of days from transplantation to date of completely healed wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney graft survival</measure>
    <time_frame>10 years</time_frame>
    <description>Number of failed kidneys evaluated with Kaplan-Meyer method. Failure defined as return to dialysis, death, retransplantation or graft removal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus Oral Product</intervention_name>
    <description>Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  End stage kidney failure&#xD;
&#xD;
          -  Negative CDC crossmatch&#xD;
&#xD;
          -  Female patients of childbearing age must have a negative pregnancy test&#xD;
&#xD;
          -  Patient must have signed the Patient Informed Consent Form.&#xD;
&#xD;
          -  Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaver transplant,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding.&#xD;
&#xD;
          -  Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, ATG, Tacrolimus&#xD;
&#xD;
          -  Patient has malignancy or history of malignancy, with the exception of adequately&#xD;
             treated localized squamous cell or basal cell carcinoma, without recurrence.&#xD;
&#xD;
          -  Patient has been included in another clinical trial protocol for any investigational&#xD;
             drug within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Patient has any form of substance abuse or psychiatric disorder or condition, which&#xD;
             invalidate communication.&#xD;
&#xD;
          -  Severe cardiac failure or severe liver failure diagnosed at the time of&#xD;
             transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frantisek Saudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Frantisek Saudek</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

